Published 17 February 2009, doi:10.1136/bmj.b566
Cite this as: BMJ 2009;338:b566

Editorials

Use of melanotan I and II in the general population

Is unlicensed, unregulated, and potentially harmful

The first 150 words of the full text of this article appear below.

In 2002 the media reported that the demand for synthetic melanocortin analogues melanotan I and melanotan II (melanotans) was likely to increase in the general population.1 This was mainly because of their ability to tan the skin, and—in the case of melanotan II—induce penile erections and increase sexual desire.2 In 2008, several workers at needle and syringe programmes in the United Kingdom contacted the substance use team at the Centre for Public Health, Liverpool, for information on "melanotan" after their clients reported injecting these drugs. Over the next year around 30 needle and syringe programmes in England and Wales and several drug workers and drug and alcohol action team commissioners have sought our advice in relation to the use of these drugs within the general population.

The prevalence of the use of these drugs is unknown. Even though the drugs are unlicensed they are easily available through online shops (including, . . . [Full text of this article]

Michael Evans-Brown, researcher in performance enhancing drugs1, Rob T Dawson, responsible medical officer 2, Martin Chandler, interagency drug misuse database manager1, Jim McVeigh, reader in substance use epidemiology1

1 Centre for Public Health, Faculty of Health and Applied Social Sciences, Liverpool John Moores University, Liverpool L3 2AY, 2 Drugs in Sport Clinic and Users’ Support, Rowlands Gill, Tyne and Wear NE39 1DU

m.j.evans-brown@ljmu.ac.uk


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Rapid Responses:

Read all Rapid Responses

Malignant Melanoma in a user of Melanotan I
Robert A Ellis, et al.
bmj.com, 26 Feb 2009 [Full text]
Usage of unlicensed drugs that are undergoing preclinical and clinical development: an unspecified risk
Scott Stevenson
bmj.com, 27 Feb 2009 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ